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SUMMARY
To identify factors preferentially necessary for driving
tumor expansion, we performed parallel in vitro and
in vivo negative-selection short hairpin RNA (shRNA)
screens. Melanoma cells harboring shRNAs target-
ing several DNA damage response (DDR) kinases
had a greater selective disadvantage in vivo than
in vitro, indicating an essential contribution of these
factors during tumor expansion. In growing tumors,
DDR kinases were activated following hypoxia.
Correspondingly, depletion or pharmacologic inhibi-
tion of DDR kinases was toxic to melanoma cells,
including those that were resistant to BRAF inhibitor,
and this could be enhanced by angiogenesis
blockade. These results reveal that hypoxia sensi-
tizes melanomas to targeted inhibition of the DDR
and illustrate the utility of in vivo shRNA dropout
screens for the identification of pharmacologically
tractable targets.
INTRODUCTION
It is well established that many cancers are ‘‘addicted’’ to certain
altered genes, a vulnerability that can be exploited therapeuti-
cally. Equally interesting is the premise that tumors express
genes that are not mutated, but to which they are addicted none-
theless. Owing to several stress factors, including adaptation to
their microenvironment, cancer cells are under continuous se-
lective pressure to survive. This requires substantial deregulation
of unmutated signaling factors, and also this phenomenon can
create tumor-specific dependencies. Targeting this ‘‘non-onco-
gene addiction’’ therefore represents a complementary tactic to
exploiting oncogene addiction (Luo et al., 2009). This strategy
builds on the concept of ‘‘synthetic lethality,’’ which is based
on the principle that a single (genetic) perturbation is compatible
with cell viability, but a second concomitant alteration is lethal
(Kaelin, 2005). It was not until the completion of the human
genome sequence as well as the availability of genome-wide
RNAi that the concept of synthetic lethality could be translated
to experimental mammalian systems.
Several examples illustrate the feasibility of drug effectiveness
and selectivity in the context of non-oncogene addiction and syn-
thetic lethality. For example, BRCA1/2-deficient breast cancers
are highly sensitive to inhibitors targeting PARP (Farmer et al.,
2005; Sharma and Settleman, 2010). Similarly, in BRAF mutant
melanomas, there is a strict requirement for MEK (Flaherty
et al., 2012; Kaelin, 2004; Sawyers, 2005; Solit et al., 2006) and
ERK (Chapman et al., 2011; Hauschild et al., 2012; Morris et al.,
2013). In addition, melanoma cells are highly dependent on pyru-
vate dehydrogenase kinase (PDK1), the gatekeeper enzyme link-
ing glycolysis to the citric acid cycle (Kaplon et al., 2013). These
examples suggest that also the ‘‘non-oncogenome’’ ought to
be exploited for drug-target discovery.
Both the limited number of clinically approved targeted drugs
available and the challenging problem of common drug resis-
tance, which can be highly pleiotropic (Jang and Atkins, 2013),
underscore the need to identify novel factors amenable to tar-
geted interference. Systematic gene silencing by RNAi libraries
in cancer cells has proven to reveal such unforeseen cellular
dependencies. However, because these experiments are
commonly performed in vitro, they ignore the effects of in vivo
parameters on both tumor progression and drug response. The
complex and harsh conditions resulting from tumor expansion
such as nutrient deprivation, limited oxygen availability, and
the generation of reactive oxygen species (Lee and Herlyn,
2007) are difficult to mimic in cell culture. It is likely, therefore,
that the functional mining of ‘‘druggable’’ targets has been far
from complete and that, particularly under in vivo conditions,
additional factors that are essential for tumor expansion can be
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unmasked. Therefore, we set out to perform parallel in vivo and
in vitro negative-selection short hairpin RNA (shRNA) screens for
genes that preferentially contribute to tumor cell proliferation and
survival in vivo.
RESULTS
Xenografted Human Melanomas Accommodate Large
Library Complexities with Minimum Random Loss
A rate-limiting requirement for a negative-selection shRNA
screen in tumors is the prevention of random loss of cells, and
thereby shRNAs, which is seen when only a fraction of the cells
contribute to the expanding tumor mass. In most human tumor
types, only specific subpopulations of cells are endowed with
tumorigenic potential when transplanted into immune-compro-
mised mice (Shackleton et al., 2009). Also for melanomas,
the presence of tumor-initiating cells has been reported (Boiko
et al., 2010; Roesch et al., 2010; Schatton et al., 2008).
However, specific modifications in the xenotransplantation
methods strongly increase the efficiency of melanoma forma-
tion (Quintana et al., 2008, 2010). In particular, when tumor
cells are embedded in Matrigel and inoculated into severely im-
mune-compromised NOD/SCID IL2Rgnull (NSG) mice human
melanomas develop faster and more efficiently, even when
inoculated as single cells. Because under these condi-
tions most melanoma cells have tumor-forming potential, we
selected this tumor type and mouse model for the screens out-
lined below.
To investigate whether such conditions are compatible
with negative-selection screening of high-complexity shRNA li-
braries, we first performed a proof-of-principle experiment using
a GFP-tagged library comprising 2,600 barcodes (noncoding
semirandom DNA sequences), which do not affect cellular
fitness. This library has been employed successfully to dissect
T cell lineage relationships previously (Gerlach et al., 2013;
Schepers et al., 2008). Our feasibility experiment was based on
the premise that similar recoveries of the barcodes from inde-
pendent tumors would indicate that a sufficient number of cells
participate in tumor establishment. The barcode library was
introduced into melanoma cells by retroviral transduction using
a low multiplicity of infection (MOI) to ensure that each cell
received one barcode copy only. GFP-positive cells were sorted
and inoculated subcutaneously (s.c.) into two NSG mice
(Figure 1A). We removed the tumors from the mice when they
reached a measurable size and subsequently analyzed the
distribution of barcodes.
Genomic DNA isolated from each tumor was divided into two
half-samples, and a ‘‘self-self’’ test showed that the ratio be-
tween barcodes detected in each sample was close to one for
both tumors (Figure S1), indicating that the prevalence of individ-
ual genetic tags could be reproducibly quantified. This result also
predicted that statistically significant outliers in self-nonself
comparisons (in an shRNA screen) would be real. More impor-
tantly, comparison of the two biological replicates showed a
remarkably large overlap of barcodes (Figure 1B). This indicated
that in independent transplanted melanomas, a sufficient num-
ber of cells contribute to tumor establishment and confirmed
the feasibility of a large-scale dropout screen in vivo.
Differential shRNA Depletion in Cultured Cells and
Expanding Tumors
To perform parallel in vitro and in vivo screens, we assembled
an shRNA library targeting500 human kinases (and related fac-
tors), with approximately five shRNAs per gene. The aim was to
detect shRNAs that are selected against in vivo, but not or to
a lesser extent in vitro, to identify pharmacologically tractable
factors critically contributing to tumor expansion. Human mela-
noma cells were transduced with four lentiviral pools, together
encoding the shRNA kinome library, and subsequently pharma-
cologically selected for successful integration and expression
(Figure 1C). Two days postinfection, two independent reference
samples were collected tomake an inventory of the shRNAs pre-
sent at the start of the screens. The remaining cells were split in
two, and the first group was resuspended in Matrigel and imme-
diately transplanted s.c. into six NSGmice. Becausewe aimed to
identify shRNAs preferentially depleted in expanding tumors
relative to an in vitro setting, we maintained the second group
of cells in parallel in culture. This was done in six independent
cell culture plates and for approximately the same period that
the tumors were expanding in mice. Once the tumors had
reached 60–100 mm3, they were removed from the mice and
genomic DNA was extracted, as well as from the cultured tumor
cells. We used PCR amplification of the shRNAs followed by
deep sequencing for the recovery and quantification of shRNAs
present in each sample.
To select genuine ‘‘dropouts,’’ that is, shRNAs that were
depletedduringeither in vitropropagation orduring tumor expan-
sion in vivo, we performed a strict quality-control analysis on
the sequencing data. The number of shRNAs detected in each
sample demonstrated that the library complexity was very well
maintained in all samples in vitro and in vivo: approximately
93% of the shRNAs that were detected in the reference samples
were reproducibly observed in cultured cells, while 85% of the
shRNAs originally present were retrieved from the tumors (Fig-
ure 1D). Similar to what was seen for the barcode experiment,
we observed a high correlation between independent biological
replicates (Figure 1E). Unsupervised analysis showed clustering
of all samples within each biological group, indicating that
random changes were minor relative to the difference between
in vitro and in vivo tumor growth (Figure 1F). Corroborating the
results from the barcode screen, these data predict that the likeli-
hood of selecting false-positive hits was minimal.
Identification and Validation of In Vivo shRNA
Dropout Hits
To call hits, that is, to identify genes with a significant role in vivo,
we applied several criteria. First, we selected genes for which at
least two independent shRNAs were significantly depleted in
tumors compared to both the references and the cultured cells
(Figures 2A, 2B, and S2A). Second, we filtered out genes for
which two or more shRNAs were depleted from cultured cells
compared to the references (Figure S2B). For example, one
gene that failed to score as a hit based on these stringent criteria
isBRAF. Themutant form ofBRAF acts as the driver oncogene in
melanoma (Davies et al., 2002), and its depletion induces cell
death both in vitro and in vivo (Hingorani et al., 2003; Tsai et al.,
2008). Indeed, although we observed loss of BRAF-targeting
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shRNAs, this occurred to similar extents in vitro and in vivo (Fig-
ure S3A); hence, BRAF failed to classify as a preferential in vivo
target. Seven genes did meet our criteria: they were depleted
by two or more shRNAs to a significantly greater extent in vivo
than in vitro (Figure 2A). The identification in the screen of
FRAP1, encoding mTOR, was reassuring because of the estab-
lished role it plays in melanoma (Karbowniczek et al., 2008).
Critical Role for DNA Damage Response Factors during
Melanoma Expansion
A key advantage of large-scale shRNA screening, in addition to its
unbiased nature, is the possibility of identifying multiple pathway
components rather than single factors. We noted that two out of
the seven screen hits were key kinases involved in the DNA dam-
age response (DDR), ATM and Chek1, while Chek2 scored with
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Figure 1. Parallel In Vitro and In Vivo
Screens Show Differential shRNA Depletion
(A) Scheme of the barcode screen. 888mel human
melanoma cells were transduced with a retroviral
GFP-tagged barcode library (MOI < 0.2). After
fluorescence-activated cell sorting, cells were
transplanted s.c. into two NSG mice. Genomic
DNA from each tumor was divided into two half-
samples. Barcodes from each were amplified,
labeled with Cy3 (A) and Cy5 (B), and hybridized to
a microarray platform containing the entire library.
See also Figure S1.
(B) Comparison of barcode representation in
two independent tumors. Each dot represents a
unique barcode. The y and x axes show the
log10 fluorescence intensity as a measure of
barcode representation in tumor 1 (half-samples
A and B) compared to tumor 2 (half-samples A
and B).
(C) Scheme of the in vivo and in vitro screens. The
lentiviral kinome library was divided into four
pools and used to transduce 888mel cells (MOI <
0.2). After puromycin selection, two reference
samples were collected. The remaining cells were
split and either transplanted s.c. into six NSG
mice (one flank each) or plated into six indepen-
dent plates for in vitro culturing. Thirteen days
later, genomic DNA was isolated and deep
sequencing was used to quantify the shRNAs
present in each sample.
(D) Library quantification. Each bar shows the
average number of different shRNAs per biological
group of samples. References serve as a control.
From 3,195 shRNAs detected in the references,
3,121 were identified in cultured cells and 3,020 in
tumors. Dark areas of the bars represent shRNAs
that were shared between all six biological repli-
cates, which account for 93% in vitro and 84.3%
in vivo.
(E) Comparison of biological replicates. Each dot
represents a unique shRNA. The x and y axes
show the log10 abundance of shRNAs. A repre-
sentative example of two biological replicates is
shown per group. Average-adjusted R2 values are
0.94, 0.89, and 0.76 for references, cultured cells,
and tumor correlations, respectively.
(F) Global view of biological similarity as illustrated
by the Euclidean distance heatmap, indicating the
degree of similarity between samples (see color
key). Light blue bars plotted inside color key
represent counts of individual heatmap units (in-
dividual correlations) with the assigned Euclidean
distance value.
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one shRNA. Because it is an established substrate of ATM, we
included Chek2 in the subsequent validation. In the screen,
shRNAs targeting these three genes were more strongly selected
against in vivo than in vitro, resulting in some cases in their com-
plete loss in tumor xenografts (Figures S3B–S3D).
To validate these results, we stably knocked down these three
genes one by one, inoculated themelanoma cells into NSGmice,
and monitored tumor growth. Silencing of CHEK1, CHEK2, or
ATM, each with independent shRNAs, profoundly delayed tumor
growth (Figures 3A–3C). CHEK1 shRNA #2 and CHEK2 shRNAs
#1 and #2 particularly showed minimal effect on cell viability
in vitro but caused strong tumor inhibition in vivo (Figures 3A–
3C, inserts). We did not observe major differences in the expres-
sion levels of the proliferation marker PCNA in cell cultures
versus tumor cells that grew in mice (Figure S3E), suggesting
that this cannot account for the observed differential sensitivity
to CHEK1, CHEK2, or ATM depletion. The average weights
of shCHEK1, shCHEK2, and shATM tumors extracted at the
endpoint of the experiment were significantly lower than those
of control tumors (Figures S3F–S3H). Notably, whereas an
efficient knockdown of all these genes was confirmed before
injection, tumors that eventually grew out had restored their
expression, consistent with the idea that silencing of any of these
DDR genes is incompatible with melanoma outgrowth in vivo
(Figures 3D–3F). Taken together, these observations indicate
that three established DDR kinases individually have essential
roles in driving melanoma expansion.
TheDNADamageResponse Pathway Is Activated during
Tumor Expansion In Vivo
We next investigated why deprivation of DDR factors confers a
strong selective disadvantage onto expanding melanomas. We
hypothesized that the DDR may be induced as a function of tu-
mor expansion. Indeed, six out of six melanomas established
in mice displayed increased phosphorylation of ATM, Chek1,
and Chek2 relative to cells cultured in vitro (Figure 4A). When
monitoring the dynamics of this phenomenon in an independent
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Figure 2. Identification of In Vivo shRNA
Dropout Hits
(A) Venn diagram illustrating the overlap of the
three independent analyses. The seven genes in
the intersection of tumors versus cultured cells and
tumors versus references were selected as hits
with a preferential effect in vivo.
(B) DESeq analysis comparing tumors versus
cultured cells. The x axis shows the log10 average
shRNA abundance across all samples. The y axis
shows the log2 fold change of tumors versus
cultured cells. Symbols distinguish shRNAs that
are significantly depleted in tumors compared to
cultured cells (triangles, true) from the unchanged
or nonsignificant ones (circles, false). Each color
represents a gene selected as a hit. See also
Figure S2.
experiment, we found no evidence for
activation of the DDR pathway in the first
week after transplantation (Figure 4B).
This result argues that the DDR was not induced artificially
because of the mere transfer of the cells from cell culture dishes
into animals. In contrast, we consistently observed induction of
these DDR factors from 2 weeks post-inoculation onward, until
the time that tumors reached 500 mm3. The activation of these
DDR kinases coincided with the phosphorylation of an array of
ATM/ATR substrates. The same pattern on the levels of DDR fac-
tors was observed when transplanting a different cell line, ruling
out cell-type-specific effects (Figure S4A).
DDR Signaling Is Induced by Hypoxia and HIF1a
Signaling In Vitro and Colocalizes with Hypoxic Areas of
Tumors In Vivo
DDR signaling can be activated in response to different kinds of
environmental and endogenous stress signals. In order for tu-
mors to expand, a key obstacle to overcome is to proliferate
and survive under suboptimal conditions. This includes the
lack of proper vasculature, necessary for transporting nutrients
and oxygen (Pouysse´gur et al., 2006). In fact, hypoxia can acti-
vate ATM and ATR checkpoints, and hypoxic tumor cells display
defective DNA repair, increased mutation rates, and chromo-
somal instability (Bencokova et al., 2009; Hammond et al.,
2007; Olcina et al., 2010). Expanding tumors had abundant levels
of Hypoxia-Inducible Transcription Factor 1a (HIF1a), the master
transcription factor controlling cellular adaptation to low oxygen
levels (Figure 5A). Following its stabilization, DDR signaling was
induced. That this link between hypoxia and DDRmay be causal
was further suggested by the strong increase in phosphorylation
of both ATM and Chek2, which followed the induction of HIF1a
by hypoxia in vitro (Figure 5B).
Under hypoxic conditions, HIF1a becomes stabilized, allowing
for dimerization with HIF1b and inducing an arsenal of genes
to help cells cope with harsh microenvironmental conditions
(Pouysse´gur et al., 2006). HIF1a stabilization can be achieved
also chemically by dimethyloxalylglycine (DMOG), which inhibits
its degradation. Exposure of cells to DMOG stabilized HIF1a,
which was accompanied by increased phosphorylation of
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Figure 3. Critical Role for DNA Damage Response Factors during Melanoma Expansion
(A) Tumor growth of 888mel cells stably transduced with shRNAs targeting CHEK1 or LUC and injected s.c. into both flanks of five NSG mice. **p = 0.006;***p =
0.0009. Data are presented as mean ± SEM. Inserts show stainings of transduced cells plated in equal numbers and grown in vitro for 8 days. See also Figures
S3B and S3F.
(B) Tumor growth of 888mel cells stably transduced with shRNAs targeting CHEK2 or LUC and injected s.c. into both flanks of NSG mice (five mice per group).
***p = 0.0009;****p < 0.00001. Data are presented as mean ± SEM. Inserts show stainings of transduced cells plated in equal numbers and grown in vitro for
8 days. See also Figures S3C and S3G.
(C)Tumorgrowthof888melcellsstably transducedwithshRNAs targetingATMorLUCand injecteds.c. intobothflanksofNSGmice (fivemicepergroup). **p<0.007.
Data are presented asmean±SEM. Inserts show stainings of transduced cells plated in equal numbers and grown in vitro for 8 days. See also Figures S3D andS3H.
(D–F) Chek1, Chek2, and ATM expression was analyzed by western blotting before in vivo transplantation and in tumors at the end of the experiment. b-Actin and
Hsp90 serve as loading controls. Densitometry measurements of bands were performed on each blot, and adjusted values relative to loading controls are shown
bellow the respective bands (Quant).
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particularly Chek1 and Chek2, indicating that HIF1a can induce
(at least these aspects of) DDR activation (Figure 5C).
To assess an in vivo correlation between hypoxia and DDR,
we performed a series of immunohistochemical stainings of
phospho-Chek2, phospho-ATM/ATR substrates and gH2AX
on xenografted tumors (Figure 5D). This analysis revealed that
the hypoxic areas in the tumors, as illustrated by the hematox-
ylin and eosin (H&E) staining showing many pyknotic/necrotic
cells (see inset) and highlighted by the staining of pimonidazole,
corresponded to the DDR areas as indicated by the intense
staining of phospho-ATM/ATR substrates and gH2AX.
Although few cells were positive for phospho-Chek2 staining,
the positive cells were distinguishably localized in the areas
where other DDR proteins were highly expressed. Furthermore,
melanoma cells showed high Ki67 expression throughout the
entire tumor.
HIF Stabilization Sensitizes Melanoma Cells to Chek1/2
Inhibition In Vitro
Since melanoma cells under hypoxic conditions and with
induced levels of HIF1a exhibited increased DDR, we hypothe-
sized that they may be more sensitive to the effects of pharma-
cologic Chek1/2 inhibition. Exposure to either AZD7762, an
inhibitor that blocks Chek1/2 activity (Figure S5A), or DMOG
caused little melanoma cell death in vitro. In contrast, combina-
tion of these compounds caused massive melanoma cell death,
as illustrated by PARP cleavage and cell viability assays for
several melanoma cell lines (including 888mel in which the
screen was performed; Figures 6A and 6B). Of note, this effect
appeared to be shared by BRAF and NRAS mutant melanomas
and independent of TP53 mutational status or activity (Fig-
ure S5B; Table S1). The effect of DMOG was dependent
on HIF signaling, since depletion of ARNT (encoding HIF1b, the
essential partner of HIF1a) protected DMOG-treated cells from
death upon Chek1/2 inhibition (Figures 6C, S5C, and S5D).
Because the emergenceof resistance toBRAF inhibition poses
a major clinical challenge, we also determined the sensitivity to
Chek1/2 inhibition in combination with DMOG in two sets of
matched treatment-naive and BRAF-inhibitor-resistant cell lines.
The resistant cell lines were as sensitive to the combination treat-
ment as their parental counterparts (Figure 6D). To determine
whether this could be recapitulated in a clinically more relevant
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Figure 4. The DNA Response Pathway Is Activated during Tumor Expansion In Vivo
(A) Western blot analysis for DDR activation of 888mel cells grown in vitro versus 888mel tumors grown subcutaneously for 3 weeks in both flanks of three mice.
(B) In vivo time course experiment. For each time point, two mice were s.c. injected with 888mel cells (both flanks) and tumors were harvested 1, 2, and 3 weeks
after inoculation as indicated and analyzed by western blotting for activation of DDR factors. Hsp90 and Cdk4 serve as loading controls. See also Figure S4.
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setting, we established low-passage cell lines from patient-
derived xenografts (PDX; M026) of a melanoma patient prior
to therapy and after resistance to vemurafenib treatment had
occurred (Figure S5E). Again, we observed a strong combinato-
rial effect also for the resistant cells, suggesting abroad effective-
ness of this antitumor strategy in melanoma (Figure 6D).
Hypoxia Enhances Tumor Killing by Pharmacological
Chek1/2 Inhibition In Vivo
The results shown above raise the possibility that reduced oxy-
gen conditions render melanoma cells more vulnerable to inhi-
bition of the DDR, providing a rationale for pharmacological
modulation of both of these factors in vivo. To explore this
A B
C D
Figure 5. DDR Signaling Is Induced by Hypoxia and HIF1a Signaling In Vitro and Colocalizes with Hypoxic Areas of Tumors In Vivo
(A) In vivo time course experiment. For each time point, two mice were s.c. injected with 888mel cells (both flanks) and tumors were harvested 1, 2, and 3 weeks
after inoculation and analyzed for HIF1a expression and DDR activation. Two tumors were analyzed per time point. Arrowhead points at phospho-Chek1. Cdk4
serves as loading control.
(B) 888mel cells were cultured under regular in vitro conditions (21% O2) or reduced oxygen tension (1% O2) for different periods of time as indicated.
Doxorubicin (Doxo) treatment serves as a positive control for phosphorylation of DDR proteins. Arrowhead points at phospho-Chek1. b-Actin serves as loading
control.
(C) 888mel cells were treated with different concentrations of DMOG for 1 day and analyzed for phosphorylation of Chek 1 and 2. Hsp90 serves as loading control.
(D) Microphotographs of H&E and pimonidazole stainings as well as immunohistochemistry of gH2AX, phospho-Chek2, phospho-ATM/ATR substrates, and Ki67
of a representative xenografted tumor harvested 1 week after s.c. injection. The hypoxic areas in the tumor are the areas with many pyknotic/apoptotic cells as
illustrated by H&E stainings, which are highlighted by pimonidazole stainings. The same areas are strongly positive for gH2AX and, to a lesser extent, phospho-
ATM/ATR substrates. Although very few cells are positive for phospho-Chek2, the positive ones are restricted to the hypoxic areas. Tumors cells are generally
positive for Ki67 throughout the entire tumor. Squares indicate insets. Scale bars represent 500 mm (2.53) and 20 mm (403, insets).
Cell Reports 9, 1375–1386, November 20, 2014 ª2014 The Authors 1381
possibility, we first used the AZD7762 compound to treat mice
immediately after transplantation of human melanoma cells.
This single agent treatment significantly delayed tumor
outgrowth, again illustrating the in vitro/in vivo window seen in
the screens (Figure S6A). Systemic drug toxicity was not
observed. Control tumors had large necrotic areas that were
largely confined to the inner tumor mass, indicative of insuffi-
cient oxygen supply. Although AZD7762-treated tumors were
smaller, they were much more necrotic and these areas
extended well beyond the tumor centers (Figure S6B). Of
more clinical relevance, a similar extent of tumor suppression
was achieved upon treatment after tumors had already estab-
lished (Figure 7A), excluding that the effect seen after Chek1/2
inhibition was simply due to a consequence of impairment of
early tumor cell engraftment.
Above, we showed that a low-passage PDX-derived cell
line from a melanoma patient with acquired resistance to
vemurafenib could be effectively eliminated by Chek1/2 inhibi-
tion in combination with DMOG. Next, we determined the
treatment response of a PDX from a patient with primary resis-
tance to vemurafenib (Figure S6C). Chek1/2 inhibition after
establishment of the xenograft strongly delayed tumor growth
(Figure 7B).
Finally, we set out to recapitulate in vivo the cooperative
induction of tumor cell death upon hypoxia and DDR inhibition
that we had observed in vitro. Treatment of transplanted
melanoma cells with the monoclonal antibody bevacizumab,
which neutralizes VEGF, accelerated the appearance of
large hypoxic areas surrounding necrotic tumor fields after
1 week of tumor transplantation (Figure 7C). More importantly,
when bevacizumab and AZD7762 were used in combination,
synergistic tumor inhibition was achieved (Figures 7D and
S6D). Similarly, synthetic lethality by hypoxia induction and
Chek1/2 inhibition in vivo was observed for the PDX derived
from a melanoma patient who had acquired resistance
to BRAF inhibition (‘‘M026R.X2’’; Figure 7E). We conclude from
these results that the combined inhibition of DDR kinases and in-
duction of hypoxia represents a potentially valuable treatment
option for melanoma, inclusively in the context of BRAF-inhibi-
tor-resistant tumor cells.
A B
C D
Figure 6. HIF Stabilization Sensitizes Melanoma Cells to Chek1/2 Inhibition In Vitro
(A) 888mel, D10, skmel28, A875, skmel147, andWM1366 humanmelanoma cell lines were plated in equal numbers and exposed to AZD7762 (80 nM for 888mel;
600 nM for D10; 160 nM for skmel28 and A875, 10 nM for skmel147 and 15 nM for WM1366), DMOG (1 mM for 888mel and skmel28; 1.5 mM for D10 and A875;
0.25mM for skmel147 and 0.75mM for WM1366) either alone or in combination as indicated. Plates were stained after 6 days.
(B) 888mel cells were treatedwith AZD7762 (80 nM), DMOG (1mM), or the combination for 6 days. Cell lysates were analyzed bywestern blotting for the indicated
antibodies. Arrowhead points at cleaved PARP. Cdk4 serves as a loading control.
(C) 888mel cells carrying either shLUC or shARNT were plated at equal numbers and exposed to AZD7762 (80 nM), DMOG (1 mM), or the combination. Plates
were stained after 6 days. See also Figures S5C and S5D.
(D) BRAF-inhibitor-naive and BRAF-inhibitor-resistant cell line pairs were treated with AZD7762 (80 nM for 888mel and 888melR, A375 and A375R; 20 nM for
M026 andM026R.X1), DMOG (1 mM for 888mel and M026.X1 pairs and 1.5 mM for A375 pair), or the combination for 6 days. M026 refers to a melanoma patient
from whom PDX-derived cell lines were generated prior to treatment (‘‘Naive’’) and after relapse (‘‘Resistant’’). See also Figure S5E.
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DISCUSSION
This study aimed to identify pharmacologically tractable cancer
targets by building on a fundamental principle: non-oncogene
addiction in vivo. We reasoned that physiologic experimental
conditions could identify critical cancer vulnerabilities that would
not readily be discovered in cells cultured in vitro. Indeed, in vivo
negative-selection screens can uncover specific dependencies
(Beronja et al., 2013; Meacham et al., 2009; Possemato et al.,
2011). For melanoma, single cells can drive tumor growth (Quin-
tana et al., 2008, 2010). Here, by genetic barcoding, we demon-
strate and exploit a related property, that is, that melanoma cells
under such conditions contribute to tumor growth in a polyclonal
fashion. It is particularly the latter property that enabled us to
perform a negative-selection screen: had the tumors been
formed in a (oligo)clonal fashion, most of the shRNA library would
have been lost randomly.
The parallel in vitro and in vivo screens demonstrated a more
profound requirement for DDR kinases for survival of melanoma
cells when proliferating in mice than upon passaging in culture.
We show that this is caused, at least in significant part, by
increased HIF-mediated hypoxic signaling, which leads to DDR
activation in vivo. Consistent with this, tumor cells are under
selective pressure to manipulate their microenvironment by
secreting soluble factors, including proangiogenic factors to
counteract the lack of blood vessels (Pouysse´gur et al., 2006).
Recapitulating one critical aspect of these conditions in vitro,
we show that hypoxia activates DDR signaling and sensitizes
tumor cells to Chek1/2 inhibition. This is consistent with, and ex-
tends, previous data on the relationship between hypoxia and
activation of the DDR pathway (Bencokova et al., 2009; Ham-
mond et al., 2007; Olcina et al., 2010), which does not always
require actual DNA damage (Hammond et al., 2007). Also, DNA
replication stress has been shown to predisposemelanoma cells
to DDR inhibition (Brooks et al., 2013; Ferrao et al., 2011).
We show that in vivo, tumor expansion coincides with activa-
tion of several DDR factors, particularly Chek1, Chek2, ATM,
and ATR. Interestingly, this was accompanied by abundant acti-
vation of the histone H2AX, indicative of ATM/ATR-dependent
DDR signaling. That this was preceded by HIF1a induction is in
agreement with our finding that low oxygen levels trigger DDR
activation in a HIF-dependent manner in vitro. Consistently,
both HIF1a or HIF2a are highly expressed in melanoma and
represent poor-prognosis biomarkers (Giatromanolaki et al.,
2003; Keith et al., 2012). We show that preventing stabilization
of both HIF isoforms by HIF1b depletion protected hypoxic
tumor cells from the cytotoxic effect of Chek1/2 inhibition. This
result suggests that the induction of HIF-dependent DDR can
be exploited pharmacologically to cause melanoma cell death
in vivo, which indeed we demonstrate here.
Our study suggests that while single-agent targeting of Chek1/
2 may have a moderate therapeutic benefit, full exploitation of
this dependency requires targeting of another signal, particularly
one that contributes to DDR activation. We show here that this
second signal may be angiogenic blockage and, consequently,
the (pharmacological) induction of hypoxia. Thismodel of combi-
natorial therapy is consistent with ongoing exploration on the tar-
geting of Chek1/2 in the context of DNA-directed chemotherapy
and radiotherapy (Landau et al., 2012; Ma et al., 2011, 2012,
2013; Morgan et al., 2010; Sausville et al., 2014; Syljua˚sen
et al., 2006). Because we found evidence implicating
both ATM/Chek2 and ATR/Chek1 in response to hypoxia, and
given the crosstalk between these signaling routes (Curtin,
2012), we reasoned that pharmacological targeting of both
checkpoint kinases would be more successful under hypoxic
conditions.
It is noteworthy that Chek1/2 inhibition eliminated both BRAF-
inhibitor-sensitive and BRAF-inhibitor-resistant cells, which is
important given the common resistance of BRAF mutant mela-
nomas to targeted therapy. We also show that an antiangiogenic
drug, such as bevacizumab, is a new in vivo synthetic lethal
partner of DDR inhibition in melanomas. It is conceivable that
this combinatorial therapeutic strategy will also be effective in
other tumor types, such as breast and pancreatic cancers (in
which Chek1/2 inhibition is being explored), but this remains to
be determined.
In conclusion, we show that during melanoma expansion, the
DDR signaling pathway becomes essential in dealing with the
limited oxygen supply. Additional factors, including nutrients
and glucose deprivation, may contribute to the stress conditions
that tumors face as well. A limitation of xenotransplantation of
human tumor cells in immunodeficient mice is the absence of
immune cells, which play an important role in tumor behavior.
This notwithstanding, by demonstrating that pharmacologically
induced hypoxia synergizes with DDR inhibitors to cause
melanoma cell death, our results highlight the advantage of an
in vivo screening approach. Thus, an in vivo negative-selection
approach can be used to identify specific synthetic lethal rela-
tionships that may be explored clinically.
EXPERIMENTAL PROCEDURES
In Vivo and In Vitro Screens
To examine the feasibility of negative-selection in vivo screens, a barcode
screen was performed as described in Supplemental Experimental Proce-
dures. For shRNA screens, a lentivirus-based kinome shRNA library (four
pools) was used to transduce 888mel cells (MOI < 0.2). After puromycin selec-
tion (1 mg/ml), two reference samples were collected as controls. Next, tumor
cells (53 105 per injection) were either injected s.c. into six NSGmice or plated
into six independent plates (53 105) for in vitro culture. Tumors were removed
from the mice and cultured cells were harvested, and genomic DNA was used
to recover shRNAs by PCR amplification followed by deep sequencing.
Three analyses were performed independently in parallel: (1) tumors versus
cultured cells (log2 fold change < 1); (2) tumors versus references (log2
fold change < 2.5), and (3) cultured cells versus references (log2 fold
change < 2.5). Genes targeted with at least two shRNAs in each of the anal-
ysis were considered hits with an enhanced in vivo effect. A more detailed pro-
tocol is described in Supplemental Experimental Procedures.
In Vitro Experiments
All cell lines were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 9% fetal bovine serum (Sigma), 2 mM glutamine, 100 U/ml peni-
cillin, and 0.1 mg/ml streptomycin (all Gibco). For knockdown experiments,
shRNA (from TRC-Hs1.0; see sequence details in the Supplemental Experi-
mental Procedures) were transfected into HEK293T cells and the lentivirus-
containing supernatant was used to transduce 888mel cells, followed by puro-
mycin selection. To generate BRAF-inhibitor-resistant cell lines, 888mel and
A375 cells were exposed to increasing concentrations of PLX4720 (Selleck;
up to 3 mM). Cell viability was measured by either crystal violet staining or
CellTiter-Blue (Promega) and fluorescence determined with an Infinite M200
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Figure 7. Hypoxia Enhances Tumor Killing by Pharmacological Chek1/2 Inhibition In Vivo
(A) NSGmice were transplanted with 888mel cells (five animals per group, both flanks) and treated with 2 mg/kg AZD7762 (red line) or with vehicle control (black
line) starting after tumors had reached approximately 50 mm3. **p < 0.007. Data are presented as mean ± SEM.
(B) NSGmice were transplanted withM019.X2 cells (five animals per group, both flanks) and treated with 2mg/kg AZD7762 (red line) or with vehicle control (black
line) after tumors had reached approximately 50 mm3. *p < 0.02. Data are presented as mean ± SEM.
(C) NSG mice were transplanted with 888mel cells and treated with vehicle or 1, 2.5, or 5 mg/kg bevacizumab for 7 days (five animals per group, both flanks).
Hypoxic tumor regions are indicated by immunohistochemical detection of pimonidazole in 888mel xenografts. Scale bar represents 200 mm (53).
(legend continued on next page)
1384 Cell Reports 9, 1375–1386, November 20, 2014 ª2014 The Authors
microplate reader (Tecan). AZD7762 (Selleck), DMOG (Frontier Scientific), and
cisplatin (Accord) were used as described in the text.
In Vivo Experiments
Humanmelanoma cell lines were embedded inMatrigel 1:1 in medium and s.c.
injected into NSGmice (53 105 per injection). A more detailed protocol on pa-
tient-derived xenografts is described in Supplemental Experimental Proce-
dures. Tumor growth was measured and calculated by the formula (a*b2)/2,
with a being the longest diameter and b the perpendicular diameter.
AZD7762 (Selleck) (2–2.5 mg/kg) was dissolved in 11.3% 2-hydroxypropyl-
b-cyclodextrin (HPbCD) in 0.9%NaCl (pH 4) and administered intraperitoneally
(i.p.) three times a week. Bevacizumab (Roche) (1–5 mg/kg) was diluted
in 0.9% NaCl and administered i.p. twice weekly. Dabrafenib (Abmole)
(30 mg/kg) was dissolved in 0.5% hydroxypropyl methylcellulose (HPMC),
0.2%Tween80 and administered orally 6 days aweek. Animals were sacrificed
by cervical dislocation or CO2, and tumor volume and weight were measured.
To assess tumor hypoxia, mice were injected i.p. with 1.5 mg/kg pimonidazole
(Hypoxyprobe) in 0.9% NaCl 1 hr prior to sacrifice. Statistical analyses were
done with two-tailed t tests for two experimental group comparisons and
one-way ANOVA corrected for multiple comparisons (Holm-Sidak) when
more than two experimental groups were analyzed (Prism; GraphPad Soft-
ware). Tumor volumes and weights at the experimental endpoints were used
for analyses. Animal experiments were performed following local and interna-
tional regulations and ethical guidelines and have been authorized by the local
experimental animal committee at The Netherlands Cancer Institute.
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